Macrogenics, Inc.

Macrogenics, Inc. company information, Employees & Contact Information

MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies.  Our team of 300+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer. Our products and platforms have attracted multiple partnerships with leading pharmaceutical and biotechnology companies around the globe. The Company considers its employees to be its most valuable asset and we are committed to providing opportunities for individuals to learn and grow as a means to further their professional development. MacroGenics' corporate culture promotes an atmosphere of innovation, open communication and teamwork where employees can see firsthand how they contribute to the success of the organization.

Company Details

Employees
399
Founded
-
Address
9704 Medical Center Drive, Rockville,md 20850,united States
Phone
3012515321
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Rockville, MD
Looking for a particular Macrogenics, Inc. employee's phone or email?

Macrogenics, Inc. Questions

News

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference GlobeNewswire

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results - Yahoo Finance

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results Yahoo Finance

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities - GlobeNewswire

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities GlobeNewswire

MacroGenics Appoints Eric Risser as President and Chief Executive Officer - GlobeNewswire

MacroGenics Appoints Eric Risser as President and Chief Executive Officer GlobeNewswire

MacroGenics CEO Scott Koenig, M.D., Ph.D., To Step Down - citybiz

MacroGenics CEO Scott Koenig, M.D., Ph.D., To Step Down citybiz

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA® - Business Wire

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA® Business Wire

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - GlobeNewswire

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 GlobeNewswire

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA - citybiz

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA citybiz

MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results - Yahoo Finance

MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results Yahoo Finance

MacroGenics Announces Date of First Quarter 2025 Financial Results - GlobeNewswire

MacroGenics Announces Date of First Quarter 2025 Financial Results GlobeNewswire

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call - GlobeNewswire

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call GlobeNewswire

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement - GlobeNewswire

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement GlobeNewswire

MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte - GlobeNewswire

MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte GlobeNewswire

MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results - Yahoo Finance

MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results Yahoo Finance

MacroGenics and EVERSANA Announce Agreement to Support the - GlobeNewswire

MacroGenics and EVERSANA Announce Agreement to Support the GlobeNewswire

MacroGenics Promotes Eric Risser to COO - citybiz

MacroGenics Promotes Eric Risser to COO citybiz

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies - Business Wire

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies Business Wire

MacroGenics Announces Sale of TZIELD Royalty Interest for up to $200M - citybiz

MacroGenics Announces Sale of TZIELD Royalty Interest for up to $200M citybiz

Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations - Investing.com

Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations Investing.com

Vobramitamab duocarmazine continues to show promise in mCRPC - Urology Times

Vobramitamab duocarmazine continues to show promise in mCRPC Urology Times

MacroGenics Appoints William Heiden to Board of Directors - citybiz

MacroGenics Appoints William Heiden to Board of Directors citybiz

MacroGenics: Working On That Road To Recovery (NASDAQ:MGNX) - Seeking Alpha

MacroGenics: Working On That Road To Recovery (NASDAQ:MGNX) Seeking Alpha

MacroGenics: Uncertain Revenue Casts A Pall (NASDAQ:MGNX) - Seeking Alpha

MacroGenics: Uncertain Revenue Casts A Pall (NASDAQ:MGNX) Seeking Alpha

MacroGenics (MGNX) Q4 2024 Earnings Call Transcript - The Motley Fool

MacroGenics (MGNX) Q4 2024 Earnings Call Transcript The Motley Fool

MacroGenics Announces Initiation of Phase 2/3 MAHOGANY - GlobeNewswire

MacroGenics Announces Initiation of Phase 2/3 MAHOGANY GlobeNewswire

MacroGenics pulls plug on vobra duo ADC after seeing phase 2 prostate cancer data - Fierce Biotech

MacroGenics pulls plug on vobra duo ADC after seeing phase 2 prostate cancer data Fierce Biotech

MacroGenics' stock crashes after 5 deaths in ADC trial - Fierce Biotech

MacroGenics' stock crashes after 5 deaths in ADC trial Fierce Biotech

Novel Combination Looks to Capitalize on Synergy of B7-H3/PD-1 Blockade - OncLive

Novel Combination Looks to Capitalize on Synergy of B7-H3/PD-1 Blockade OncLive

MacroGenics: Struggling Wheeler- Dealer Dealt Away Its Best Bets (NASDAQ:MGNX) - Seeking Alpha

MacroGenics: Struggling Wheeler- Dealer Dealt Away Its Best Bets (NASDAQ:MGNX) Seeking Alpha

MacroGenics closes solid tumor clinical trial after 7 people die - Fierce Biotech

MacroGenics closes solid tumor clinical trial after 7 people die Fierce Biotech

MacroGenics Regains Global Rights to Enoblituzumab Cancer Drug, Collaborates With Merck - Immuno-Oncology News

MacroGenics Regains Global Rights to Enoblituzumab Cancer Drug, Collaborates With Merck Immuno-Oncology News

MGNX Stock Price and Chart — NASDAQ:MGNX - TradingView

MGNX Stock Price and Chart — NASDAQ:MGNX TradingView

Advanced HER2-Positive Breast Cancer: All Eyes on These Novel Agents - The ASCO Post

Advanced HER2-Positive Breast Cancer: All Eyes on These Novel Agents The ASCO Post

FierceBiotech's 2013 Fierce 15 - Fierce Biotech

FierceBiotech's 2013 Fierce 15 Fierce Biotech

Top Macrogenics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant